Product
JNJ-67896049
Aliases
Selexipag
Name
UPTRAVI
INN Name
Selexipag
FDA Approved
Yes
1 clinical trial
1 organization
1 indication
1 document
Indication
Pulmonary Arterial HypertensionClinical trial
A Prospective, Multicenter, Single-Arm, Open-Label, Phase 4 Study of the Effects of Selexipag on Right Ventricular Remodeling in Pulmonary Arterial Hypertension Assessed by Cardiac Magnetic Resonance ImagingStatus: Terminated, Estimated PCD: 2023-07-28
Document
DailyMed Label: UPTRAVIOrganization
Actelion Pharmaceuticals US, Inc.